Real-World Observational Study Using US Pharmacy Claims Data to Assess Safety Outcomes and Treatment Patterns in the US Among Migraine Patients Treated with REYVOW (Lasmiditan) Long Term (H8H-MC-B010)

Study identification

• EU PAS number:
  EUPAS104191
• Study ID:
  104192
• Official title and acronym:
  Real-World Observational Study Using US Pharmacy Claims Data to Assess Safety Outcomes and Treatment Patterns in the US Among Migraine Patients Treated with REYVOW (Lasmiditan) Long Term (H8H-MC-B010)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Eli Lilly and Company

Study timelines

Date when funding contract was signed

Actual:10/10/2022

Study start date

Planned:31/12/2023

Date of final study report

Planned:31/12/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)